# ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma

> **NCT00352313** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 82 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** ATN-161
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT00352313
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-01
- **Final completion:** 2008-01
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2012-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352313, "ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00352313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*